These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 27347712)

  • 1. Emerging drugs for nosocomial pneumonia.
    Liapikou A; Torres A
    Expert Opin Emerg Drugs; 2016 Sep; 21(3):331-41. PubMed ID: 27347712
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Investigational drugs in phase I and phase II clincial trials for the treatment of hospital-acquired pneumonia.
    Falcó V; Burgos J; Papiol E; Ferrer R; Almirante B
    Expert Opin Investig Drugs; 2016 Jun; 25(6):653-65. PubMed ID: 26998623
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibiotic resistance in nosocomial respiratory infections.
    Denys GA; Relich RF
    Clin Lab Med; 2014 Jun; 34(2):257-70. PubMed ID: 24856527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hospital-acquired pneumonia and ventilator-associated pneumonia in adults at Siriraj Hospital: etiology, clinical outcomes, and impact of antimicrobial resistance.
    Werarak P; Kiratisin P; Thamlikitkul V
    J Med Assoc Thai; 2010 Jan; 93 Suppl 1():S126-38. PubMed ID: 20364567
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic drug evaluation of avibactam + ceftazidime for the treatment of hospital-acquired pneumonia.
    Falcone M; Viale P; Tiseo G; Pai M
    Expert Opin Drug Metab Toxicol; 2018 Mar; 14(3):331-340. PubMed ID: 29373935
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ceftobiprole medocaril: a review of its use in patients with hospital- or community-acquired pneumonia.
    Syed YY
    Drugs; 2014 Sep; 74(13):1523-42. PubMed ID: 25117196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current review of antimicrobial treatment of nosocomial pneumonia caused by multidrug-resistant pathogens.
    Jean SS; Hsueh PR
    Expert Opin Pharmacother; 2011 Oct; 12(14):2145-8. PubMed ID: 21895553
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ceftolozane-tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial.
    Kollef MH; Nováček M; Kivistik Ü; Réa-Neto Á; Shime N; Martin-Loeches I; Timsit JF; Wunderink RG; Bruno CJ; Huntington JA; Lin G; Yu B; Butterton JR; Rhee EG
    Lancet Infect Dis; 2019 Dec; 19(12):1299-1311. PubMed ID: 31563344
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Locally derived versus guideline-based approach to treatment of hospital-acquired pneumonia in the trauma intensive care unit.
    Becher RD; Hoth JJ; Rebo JJ; Kendall JL; Miller PR
    Surg Infect (Larchmt); 2012 Dec; 13(6):352-9. PubMed ID: 23268613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic drug evaluation of ceftobiprole for the treatment of MRSA.
    Horn KS; Danziger LH; Rodvold KA; Glowacki RC
    Expert Opin Drug Metab Toxicol; 2017 Apr; 13(4):463-472. PubMed ID: 28264613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ceftolozane/tazobactam and ceftazidime/avibactam: two novel β-lactam/β-lactamase inhibitor combination agents for the treatment of resistant Gram-negative bacterial infections.
    Liscio JL; Mahoney MV; Hirsch EB
    Int J Antimicrob Agents; 2015 Sep; 46(3):266-71. PubMed ID: 26143591
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New Antibiotics for Hospital-Acquired Pneumonia and Ventilator-Associated Pneumonia.
    Bassetti M; Mularoni A; Giacobbe DR; Castaldo N; Vena A
    Semin Respir Crit Care Med; 2022 Apr; 43(2):280-294. PubMed ID: 35088403
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ceftobiprole for the treatment of pneumonia: a European perspective.
    Liapikou A; Cillóniz C; Torres A
    Drug Des Devel Ther; 2015; 9():4565-72. PubMed ID: 26316697
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cephalosporins currently in early clinical trials for the treatment of bacterial infections.
    Long TE; Williams JT
    Expert Opin Investig Drugs; 2014 Oct; 23(10):1375-87. PubMed ID: 24956017
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New antibiotics for ventilator-associated pneumonia.
    Bassetti M; Vena A; Castaldo N; Righi E; Peghin M
    Curr Opin Infect Dis; 2018 Apr; 31(2):177-186. PubMed ID: 29337703
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacotherapy for hospital-acquired pneumonia.
    Liapikou A; Rosales-Mayor E; Torres A
    Expert Opin Pharmacother; 2014 Apr; 15(6):775-86. PubMed ID: 24579912
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic and pharmacodynamics evaluation of ceftobiprole medocaril for the treatment of hospital-acquired pneumonia.
    Lagacé-Wiens PR; Rubinstein E
    Expert Opin Drug Metab Toxicol; 2013 Jun; 9(6):789-99. PubMed ID: 23590397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Therapeutic Strategy for All Pneumonia Patients: A 3-Year Prospective Multicenter Cohort Study Using Risk Factors for Multidrug-resistant Pathogens to Select Initial Empiric Therapy.
    Maruyama T; Fujisawa T; Ishida T; Ito A; Oyamada Y; Fujimoto K; Yoshida M; Maeda H; Miyashita N; Nagai H; Imamura Y; Shime N; Suzuki S; Amishima M; Higa F; Kobayashi H; Suga S; Tsutsui K; Kohno S; Brito V; Niederman MS
    Clin Infect Dis; 2019 Mar; 68(7):1080-1088. PubMed ID: 30084884
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ceftobiprole medocaril in the treatment of hospital-acquired pneumonia.
    Scheeren TW
    Future Microbiol; 2015; 10(12):1913-28. PubMed ID: 26573022
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current and Future Considerations for the Treatment of Hospital-Acquired Pneumonia.
    Montravers P; Harpan A; Guivarch E
    Adv Ther; 2016 Feb; 33(2):151-66. PubMed ID: 26861846
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.